Methylated +58CpG site decreases DCN mRNA expression and enhances TGF-β/Smad signaling in NSCLC cells with high metastatic potential

International Journal of Oncology

Volumn 44, Issue 3, 2014, Pages 874-882

  Qian, Qian ^a,b   Shi, Xiangguang ^a,b   Lei, Zhe ^a,b   Zhan, Lei ^a,b   Liu, Reng Yun ^a,b   Zhao, Jun ^a,b   Yang, Binghua ^a   Liu, Zeyi ^a,b   Zhang, Hong Tao ^a,b  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b Suzhou Key Laboratory for Molecular Cancer Genetics   (China)

Author keywords

+58CpG; DCN; Methylation; NSCLC; TGF Smad signaling

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AROMATIC HYDROCARBON RECEPTOR; BISULFITE; DECORIN; DNA BINDING PROTEIN; GENOMIC DNA; MESSENGER RNA; SMAD PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN;

+58CPG SITE; 5' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER STAGING; CELL INVASION; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; COMPUTER MODEL; CONTROLLED STUDY; CPG ISLAND; CULTURE MEDIUM; DISTANT METASTASIS; DNA METHYLATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; NATIVE POLYACRYLAMIDE GEL ELECTROPHORESIS; OLIGONUCLEOTIDE PROBE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; TRANSLATION INITIATION; WESTERN BLOTTING;

CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CPG ISLANDS; DECORIN; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84896700164     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2255     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Ramsey SD, Clarke L, Kamath TV and Lubeck D: Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. J Manag Care Pharm 12: 472-478, 2006.
3. Feng J, Zhang X, Zhu H, Wang X, Ni S and Huang J: High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. Am J Clin Pathol 138: 230-235, 2012.
4. Gupta GP and Massague J: Cancer metastasis: building a framework. Cell 127: 679-695, 2006.
5. Shi Y and Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700, 2003.
6. Toonkel RL, Borczuk AC and Powell CA: TGF-beta signaling pathway in lung adenocarcinoma invasion. J Thorac Oncol 5: 153-157, 2010.
7. Akhurst RJ and Derynck R: TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol 11: S44-S51, 2001.
8. Xu Y and Pasche B: TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet 16 Spec No. 1: R14-R20, 2007.
9. Liu X, Sun Y, Constantinescu S, Karam E, Weinberg R and Lodish H: Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci USA 94: 10669-10674, 1997.
10. Velden JL, Alcorn JF, Guala AS, Badura EC and Janssen-Heininger YM: c-Jun N-terminal kinase 1 promotes transforming growth factor-beta1-induced epithelial-to-mesenchymal transition via control of linker phosphorylation and transcriptional activity of Smad3. Am J Respir Cell Mol Biol 44: 571-581, 2011.
11. Yilmaz M, Christofori G and Lehembre F: Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med 13: 535-541, 2007.
12. Goldoni S, Owens RT, McQuillan DJ, et al: Biologically active decorin is a monomer in solution. J Biol Chem 279: 6606-6612, 2004.
13. Bi X, Pohl NM, Qian Z, et al: Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis 33: 326-330, 2012.
14. Bi XL and Yang W: Biological functions of decorin in cancer. Chin J Cancer 32: 266-269, 2013.
15. Bi XL, Tong C, Dockendorff A, et al: Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis 29: 1435-1440, 2008.
16. Goldoni S, Seidler DG, Heath J, et al: An antimetastatic role for decorin in breast cancer. Am J Pathol 173: 844-855, 2008.
17. Matsumine A, Shintani K, Kusuzaki K, et al: Expression of decorin, a small leucine-rich proteoglycan, as a prognostic factor in soft tissue tumors. J Surg Oncol 96: 411-418, 2007.
18. Nash MA, Deavers MT and Freedman RS: The expression of decorin in human ovarian tumors. Clin Cancer Res 8: 1754-1760, 2002.
19. Reed CC, Gauldie J and Iozzo RV: Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 21: 3688-3695, 2002.
20. Kresse H and Schonherr E: Proteoglycans of the extracellular matrix and growth control. J Cell Physiol 189: 266-274, 2001.
21. Tralhao JG, Schaefer L, Micegova M, et al: In vivo selective and distant killing of cancer cells, using adenovirus-mediated decorin gene transfer. FASEB J 17: 464-466, 2003.
22. Yamaguchi Y, Mann DM and Ruoslahti E: Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346: 281-284, 1990.
23. Biaoxue R, Xiguang C, Hua L, et al: Decreased expression of decorin and p57(KIP2) correlates with poor survival and lymphatic metastasis in lung cancer patients. Int J Biol Markers 26: 9-21, 2011.
24. Liu Z, Zhao J, Chen XF, et al: CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer. Lung Cancer 62: 15-22, 2008.
25. Liu Z, Li W, Lei Z, et al: CpG island methylator phenotype involving chromosome 3p confers an increased risk of non-small cell lung cancer. J Thorac Oncol 5: 790-797, 2010.
26. Zhang HT, Chen XF, Wang MH, et al: Defective expression of transforming growth factor beta receptor type II is associated with CpG methylated promoter in primary non-small cell lung cancer. Clin Cancer Res 10: 2359-2367, 2004.
27. Doi A, Park IH, Wen B, et al: Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 41: 1350-1353, 2009.
28. Irizarry RA, Ladd-Acosta C, Wen B, et al: The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41: 178-186, 2009.
29. Lu YL, Huang JX, Li XH, et al: Spontaneous metastasis of clonal cell subpopulations of human lung giant cell carcinoma after subcutaneous inoculation in nude mice. Chin J Oncol 11: 1-7, 1989.
30. Sun W, Guo C, Meng X, et al: Differential expression of PAI-RBP1, C1orf142, and COTL1 in non-small cell lung cancer cell lines with different tumor metastatic potential. J Investig Med 60: 689-694, 2012.
31. Shang Y, Myers M and Brown M: Formation of the androgen receptor transcription complex. Mol Cell 9: 601-610, 2002.
32. Sogawa K and Fujii-Kuriyama Y: Ah receptor, a novel ligand-activated transcription factor. J Biochem 122: 1075-1079, 1997.
33. Zhao J, Sime PJ, Bringas P Jr, Gauldie J and Warburton D: Adenovirus-mediated decorin gene transfer prevents TGF-beta-induced inhibition of lung morphogenesis. Am J Physiol 277: L412-L422, 1999.
34. Koninger J, Giese NA, di Mola FF, et al: Overexpressed decorin in pancreatic cancer: potential tumor growth inhibition and attenuation of chemotherapeutic action. Clin Cancer Res 10: 4776-4783, 2004.
35. Cairns P: Gene methylation and early detection of genitourinary cancer: the road ahead. Nat Rev Cancer 7: 531-543, 2007.
36. Lu F and Zhang HT: DNA methylation and nonsmall cell lung cancer. Anat Rec 294: 1787-1795, 2011.
37. Luczak MW and Jagodzinski PP: The role of DNA methylation in cancer development. Folia Histochem Cytobiol 44: 143-154, 2006.
38. Jeon HS and Jen J: TGF-beta signaling and the role of inhibitory Smads in non-small cell lung cancer. J Thorac Oncol 5: 417-419, 2010.